These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24958444)

  • 1. Therapeutic strategies of urinary disorders in MS. Practice and algorithms.
    Denys P; Phe V; Even A; Chartier-Kastler E
    Ann Phys Rehabil Med; 2014 Jul; 57(5):297-301. PubMed ID: 24958444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.
    De Ridder D; Van Der Aa F; Debruyne J; D'hooghe MB; Dubois B; Guillaume D; Heerings M; Ilsbroukx S; Medaer R; Nagels G; Seeldrayers P; Van Landegem W; Willekens B; Zicot AF
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2033-40. PubMed ID: 23880016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder management in multiple sclerosis.
    Yang CC
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):673-86. PubMed ID: 24314685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
    Medina-Polo J; Adot JM; Allué M; Arlandis S; Blasco P; Casanova B; Matías-Guiu J; Madurga B; Meza-Murillo ER; Müller-Arteaga C; Rodríguez-Acevedo B; Vara J; Zubiaur MC; López-Fando L
    Neurourol Urodyn; 2020 Feb; 39(2):762-770. PubMed ID: 31943361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
    Tornic J; Sartori AM; Gajewski JB; Cox A; Schneider MP; Youssef NA; Mordasini L; Chartier-Kastler E; Bachmann LM; Kessler TM
    Neurourol Urodyn; 2018 Nov; 37(8):2315-2322. PubMed ID: 29917273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm.
    Amarenco G; Chartier-Kastler E; Denys P; Jean JL; de Sèze M; Lubetzski C
    Mult Scler; 2013 Dec; 19(14):1931-7. PubMed ID: 23698129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.
    Tubaro A; Puccini F; De Nunzio C; Digesu GA; Elneil S; Gobbi C; Khullar V
    Curr Urol Rep; 2012 Oct; 13(5):335-42. PubMed ID: 22886612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series.
    Engeler DS; Meyer D; Abt D; Müller S; Schmid HP
    BMC Urol; 2015 Oct; 15():105. PubMed ID: 26498275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prospective evaluation of mouth and eye dryness induced by antimuscarinic drugs used for neurogenic overactive bladder in 35 patients with multiple sclerosis].
    Weglinski L; Manceau P; Thomas-Pohl M; Le Breton F; Amarenco G
    Prog Urol; 2017 Mar; 27(4):253-260. PubMed ID: 27955902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The overactive bladder in multiple sclerosis.
    Fingerman JS; Finkelstein LH
    J Am Osteopath Assoc; 2000 Mar; 100(3 Suppl):S9-12. PubMed ID: 10763312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines in the treatment of neurogenic bladder].
    Vale P
    Acta Med Port; 1999; 12(1-3):119-21. PubMed ID: 10423885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA and multiple sclerosis.
    Schurch B; Carda S
    Ann Phys Rehabil Med; 2014 Jul; 57(5):302-314. PubMed ID: 24953702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary management of the neurogenic bladder for multiple sclerosis patients.
    Stoffel JT
    Urol Clin North Am; 2010 Nov; 37(4):547-57. PubMed ID: 20955906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future drugs for treatment of MS-associated bladder dysfunction.
    Andersson KE
    Ann Phys Rehabil Med; 2014 Jul; 57(5):321-328. PubMed ID: 24954496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis.
    Abo Youssef N; Schneider MP; Mordasini L; Ineichen BV; Bachmann LM; Chartier-Kastler E; Panicker JN; Kessler TM
    BJU Int; 2017 Apr; 119(4):515-521. PubMed ID: 28058780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
    Phé V; Schneider MP; Peyronnet B; Abo Youssef N; Mordasini L; Chartier-Kastler E; Bachmann LM; Kessler TM
    Neurourol Urodyn; 2018 Jan; 37(1):67-82. PubMed ID: 28618110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and comparison of questionnaires in the management of spinal cord injury, multiple sclerosis and the neurogenic bladder.
    Tsang B; Stothers L; Macnab A; Lazare D; Nigro M
    Neurourol Urodyn; 2016 Mar; 35(3):354-64. PubMed ID: 25620137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of the neuro-urological patient: a systematic review.
    Averbeck MA; Madersbacher H
    BJU Int; 2015 Apr; 115 Suppl 6():39-46. PubMed ID: 25891319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower urinary tract dysfunction due to multiple sclerosis.
    Carr LK
    Can J Urol; 2006 Feb; 13 Suppl 1():2-4. PubMed ID: 16526973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms.
    Tracey JM; Stoffel JT
    Investig Clin Urol; 2016 Nov; 57(6):377-383. PubMed ID: 27847911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.